Composition for sustained release of human growth hormone
First Claim
Patent Images
1. A composition for the sustained release of human growth hormone from a polymer matrix comprising:
- a) poly(lactide-co-glycolide); and
b) particles of zinc-complexed human growth hormone, with a zinc cation component-to-human growth hormone molar ratio between about 4;
1 and about 100;
1, wherein said particles are dispersed within the poly(lactide-co-glycolide) and wherein the proportion of human growth hormone in the sustained release composition is between 10 and 30 weight percent.
0 Assignments
0 Petitions
Accused Products
Abstract
The method of the invention for producing a composition for the sustained release of biologically active hGH includes dissolving a biocompatible polymer in a polymer solvent to form a polymer solution, dispersing particles of biologically active, metal cation-stabilized hGH in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of said hGH particles.
-
Citations
12 Claims
-
1. A composition for the sustained release of human growth hormone from a polymer matrix comprising:
-
a) poly(lactide-co-glycolide); and b) particles of zinc-complexed human growth hormone, with a zinc cation component-to-human growth hormone molar ratio between about 4;
1 and about 100;
1, wherein said particles are dispersed within the poly(lactide-co-glycolide) and wherein the proportion of human growth hormone in the sustained release composition is between 10 and 30 weight percent. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A method of delivering human growth hormone to a subject in need thereof comprising the step of administering to said subject a composition for the sustained release of human growth hormone comprising:
-
a) poly(lactide-co-glycolide); and b) particles of zinc-complexed human growth hormone, with a zinc cation component-to-human growth hormone molar ratio between about 4;
1 and about 100;
1, wherein said particles are dispersed within the poly(lactide-co-glycolide) and wherein the proportion of human growth hormone in the sustained release composition is between 10 and 30 weight percent. - View Dependent Claims (8, 9, 10, 11, 12)
-
Specification